Fulgent Genetics FLGT reported Q4 results.
Quarterly Results
• Earnings per share were up 500% over the past year to $0.04, which in line with the estimate.
• Revenue of $8,387,000 up by 47.68% from the same period last year, which missed the estimate of $8,510,000.
Conference Call Details
• Date: Mar 10, 2020
• Time: 8:05 PM ET
• Webcast URL: https://edge.media-server.com/mmc/p/suwtghgd
Recent Stock Performance
• 52-week high was at $20.60
• 52-week low was at $4.71
• Price action over last quarter: Up 17.22%
Company Overview
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.